Seres Therapeutics to Present at CARB-X Investor Day
Seres Therapeutics, Inc. (MCRB)
Last seres therapeutics, inc. earnings: 11/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.serestherapeutics.com
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at the 2026 CARB-X Investor Day on April 16, 2026, which precedes the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Munich, Germany. CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global nonprofit partnership accelerating the development of new antibacterial products to address drug-resistant bacteria. The CARB-X Investor Day brings together pharmaceutical and biotech product developers, investors, and partners working to combat antimicrobial resistance (AMR). The World Health Organization declared AMR as a top ten global public health threat, with estimates that yearly deaths may reach 10 million by 2050, putting mortality due to AMR on par with deaths due to cancer. The event will feature presentations o
Show less
Read more
Impact Snapshot
Event Time:
MCRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCRB alerts
High impacting Seres Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MCRB
News
- Seres Therapeutics (MCRB) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $22.00 price target on the stock.MarketBeat
- Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesGlobeNewswire
- Microbiome Market Competitive Landscape Report 2026: Comprehensive Insights About 140+ Companies and 180+ Drugs [Yahoo! Finance]Yahoo! Finance
- Seres Therapeutics appoints Richard Kender as interim CEO [Seeking Alpha]Seeking Alpha
- Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates [Yahoo! Finance]Yahoo! Finance
MCRB
Earnings
- 3/12/26 - Beat
MCRB
Analyst Actions
- 3/13/26 - Canaccord Genuity
MCRB
Sec Filings
- 3/17/26 - Form 144
- 3/16/26 - Form 8-K
- 3/12/26 - Form 10-K
- MCRB's page on the SEC website